26 February 2020

Swiss Rockets AG: Business Advisory Committee will combine business with the patients’ well-being

To deliver breakthrough treatments to cancer patients, Swiss Rockets supports innovation through investments in the novel and differentiated ideas and technologies. Swiss Rockets’ business model, promoted by highly competent members of the Business Advisory Committee, will ensure success in transforming cancer care with new and best in class medicines.

Dr. Sabina R. Korfmann-Bodenmann

Chairman of Business Advisory Committee

Dr. Sabina R. Korfmann-Bodenmann is a specialist in the financial sector, who gained international experience in the US and India. After a successful banking career, Sabina founded Korfmann Corporate Communications Consulting AG (KCCC) in 2001, a communications company exclusively specialized in financial institutions. Today, KCCC serves leading international firms in the financial sector. Dr. Korfmann-Bodenmann is a member of several boards of directors and trustees. She has written several books, including Living Heritage – Centuries in Business (2016) and Brooklyn – Heritage Reclaimed (2017). Sabina is a Visiting Artist at the Art History Institute of the University of Zürich.

Christoph Rentsch

Vice-Chairman of Business Advisory Committee

Christoph Rentsch is a well-known expert in corporate finance as well as private and public funding markets with more than 25 years of experience in the life science field. From 1991 to 1994, Christoph was developing his professional carrier in Switzerland and the US, where he led various senior management functions for the Alusuisse-Lonza Group. Subsequently, he joined F. Hoffmann-La Roche to become Head of Group Funding and Capital Markets, responsible for all of Roche’s Finance transactions on Group level for almost 10 years. He was a partner at Caperis Ltd, a life science investment management firm, Chief Financial Officer and member of the executive committee of both Polyphor, and most recently, Santhera Pharmaceuticals. With outstanding experience in business and finances, Christoph is also a board member of TargImmune Therapeutics AG and is a partner at Independent Capital Group AG since 2020.

Manuel Ebner

Member of Business Advisory Committee and Co-Founder

Manuel Ebner is an expert in corporate finance, business strategy, corporate development, management consulting, and financial services. He graduated in engineering and economics from Stanford University and completed his MBA (Arjay Miller Scholar) at the Stanford Graduate School of Business. Manuel Ebner was a Partner at the strategy consulting firms Boston Consulting Group and McKinsey in Switzerland. He has also led several companies as CEO, among which Artificial Life Schweiz, Obtree Technologies, BZ Bank, and Merrill Lynch Capital Markets. Mr. Ebner is a member of the Zurich Committee of the Human Rights Watch and was a Chairman of the Gold Zurich Chapter of the YPO. Manuel is a co-founder and a strategic advisor of Swiss Rockets AG.

Dr. Kenneth C. Korfmann

Member of Business Advisory Committee

Dr. Kenneth C. Korfmann is an experienced professional in the fields of banking, business, and human resources consulting. In 1997 Kenneth founded the executive search firm Korfmann Burnett & Partner AG, after two years as the Partner responsible for the Financial Services Practice across Europe at another prominent international consulting firm. He previously served as the Chief Operating Officer of Coutts Bank with responsibility for all non-UK international activities of the bank, and before he was the Chief Executive Officer responsible for Private Banking at Citibank Switzerland. Kenneth is presently a member of the Senior Advisory Board of Agilitas Partners LLP and was Co-Founder and Vice Chairman of PBS Private Bank Switzerland until it was sold to Credit Suisse. He also served as Chairman of ScienceMatters, an internet open-platform science publishing company, as a non-executive member of the board at Lazard GmbH, Zürich, and as a member of the Advisory Board of the Symbiotics Group, Geneva.

Sergey Shneyerson

Member of Business Advisory Committee

Sergey Shneyerson is a founding partner of Basil Street Advisory, a strategy, private equity, and M&A advisory business. Previously, Sergey was Partner with Exigen Capital, USA, where he led the firm’s investment activities. Sergey held several senior management positions with global technology companies. At Microsoft, he led the development of cloud strategy and offerings for Microsoft Services, the largest division within the company, with over 20,000 employees worldwide. Earlier in his career, Sergey co-founded a pioneering consumer Internet business and led its acquisition by Amazon.com. Sergey also worked for the Boston Consulting Group in Chicago, advising senior management at companies in the software, financial services, and private equity industries.

About Swiss Rockets AG

Swiss Rockets AG, founded in 2018, is implementing a paradigm shift in healthcare. Cancer patients will benefit from new treatments that will be developed using innovative and disruptive methods. The Swiss-Rockets team combines the necessary knowledge and experience to efficiently and sustainably break new ground in cancer medicine.

Founder and CEO of Swiss Rockets is Dr. Vladimir Cmiljanovic, a medicinal chemist with more than 15 years’ experience in the development of cancer drugs. Together with his sister Dr. Natasa Cmiljanovic, co-founder and Chief Scientific Officer of Swiss Rockets, he developed oncology drugs at the University of Basel and subsequently founded and successfully led two biotech companies. Manuel Ebner, Strategic Advisor of Swiss Rockets and CEO Switzerland at Bank of America Merrill Lynch, and Dr. Thomas Sander, Scientific Advisor and one of the first employees of the biotech company Actelion, are co-founders of Swiss Rockets AG.

The Board of Directors of Swiss Rockets AG is chaired by Vladimir Cmiljanovic, a successful entrepreneur and the founder of Swiss biotech companies PIQUR and TargImmune. Other board members are Prof. Dr. Michael N. Hall, a renowned researcher and Professor at the Biozentrum of the University of Basel, and André Debrunner, a financial expert and fund manager at Northern Trust Corporation Switzerland.

PREVIOUS NEWS NEXT NEWS